Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter.
Griffiths GO, FitzGerald R, Jaki T, Corkhill A, Reynolds H, Ewings S, Condie S, Tilt E, Johnson L, Radford M, Simpson C, Saunders G, Yeats S, Mozgunov P, Tansley-Hancock O, Martin K, Downs N, Eberhart I, Martin JWB, Goncalves C, Song A, Fletcher T, Byrne K, Lalloo DG, Owen A, Jacobs M, Walker L, Lyon R, Woods C, Gibney J, Chiong J, Chandiwana N, Jacob S, Lamorde M, Orrell C, Pirmohamed M, Khoo S; AGILE investigators. Griffiths GO, et al. Among authors: orrell c. Trials. 2021 Jul 26;22(1):487. doi: 10.1186/s13063-021-05458-4. Trials. 2021. PMID: 34311777 Free PMC article.
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R. Dickinson L, et al. Among authors: orrell c. Clin Pharmacokinet. 2016 Jul;55(7):861-873. doi: 10.1007/s40262-015-0360-5. Clin Pharmacokinet. 2016. PMID: 26715213 Free PMC article. Clinical Trial.
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, Kaboggoza J, Sihlangu M, Coombs JA, Malaba T, Byamugisha J, Amara A, Gini J, Else L, Heiburg C, Hodel EM, Reynolds H, Mehta U, Byakika-Kibwika P, Hill A, Myer L, Lamorde M, Khoo S. Waitt C, et al. Among authors: orrell c. PLoS Med. 2019 Sep 20;16(9):e1002895. doi: 10.1371/journal.pmed.1002895. eCollection 2019 Sep. PLoS Med. 2019. PMID: 31539371 Free PMC article. Clinical Trial.
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
Kintu K, Malaba TR, Nakibuka J, Papamichael C, Colbers A, Byrne K, Seden K, Hodel EM, Chen T, Twimukye A, Byamugisha J, Reynolds H, Watson V, Burger D, Wang D, Waitt C, Taegtmeyer M, Orrell C, Lamorde M, Myer L, Khoo S; DolPHIN-2 Study Group. Kintu K, et al. Among authors: orrell c. Lancet HIV. 2020 May;7(5):e332-e339. doi: 10.1016/S2352-3018(20)30050-3. Lancet HIV. 2020. PMID: 32386721 Free PMC article. Clinical Trial.
Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
Alhassan Y, Twimukye A, Malaba T, Orrell C, Myer L, Waitt C, Lamorde M, Kambugu A, Reynolds H, Khoo S, Taegtmeyer M. Alhassan Y, et al. Among authors: orrell c. BMC Health Serv Res. 2020 Aug 1;20(1):705. doi: 10.1186/s12913-020-05580-0. BMC Health Serv Res. 2020. PMID: 32738918 Free PMC article.
Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1.
Dickinson L, Walimbwa S, Singh Y, Kaboggoza J, Kintu K, Sihlangu M, Coombs JA, Malaba TR, Byamugisha J, Pertinez H, Amara A, Gini J, Else L, Heiberg C, Hodel EM, Reynolds H, Myer L, Waitt C, Khoo S, Lamorde M, Orrell C; DolPHIN-1 Study Group. Dickinson L, et al. Among authors: orrell c. Clin Infect Dis. 2021 Sep 7;73(5):e1200-e1207. doi: 10.1093/cid/ciaa1861. Clin Infect Dis. 2021. PMID: 33346335 Free PMC article. Clinical Trial.
Evaluation of adherence monitoring system using evriMED with a differentiated response compared to standard of care among drug-sensitive TB patients in three provinces in South Africa: a protocol for a cluster randomised control trial.
Maraba N, Orrell C, Chetty-Makkan CM, Velen K, Mukora R, Page-Shipp L, Naidoo P, Mbatha MT, Fielding KL, Charalambous S. Maraba N, et al. Among authors: orrell c. Trials. 2021 Jun 9;22(1):389. doi: 10.1186/s13063-021-05337-y. Trials. 2021. PMID: 34108036 Free PMC article.
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, Read L, Read J, Stemmet LA, Mrubata M, Byrne K, Seden K, Twimukye A, Theunissen H, Hodel EM, Chiong J, Hu NC, Burger D, Wang D, Byamugisha J, Alhassan Y, Bokako S, Waitt C, Taegtmeyer M, Orrell C, Lamorde M, Myer L, Khoo S; DolPHIN-2 Study Group. Malaba TR, et al. Among authors: orrell c. Lancet HIV. 2022 Aug;9(8):e534-e543. doi: 10.1016/S2352-3018(22)00173-4. Lancet HIV. 2022. PMID: 35905752 Free article. Clinical Trial.
167 results